Although previous human clinical trials [23,24,25] and studies in rodent cancer models [26,27,28,29,30,31] confirmed therapeutic effectiveness of ghrelin or ghrelin analogues as anti-CACS treatment, currently no ghrelin-based drug is approved. Here, GHRL is linked to cancer.